Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China · Delayed Price · Currency is CNY

128.71

-9.63 (-6.96%)

Aug 21, 2026, 3:00 PM CST

SHA:688266 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,640	810.48	532.95	386.44	302.31	190.36
Revenue Growth	145.58%	52.07%	37.91%	27.83%	58.81%	588.19%
Gross Profit	1,531	728.51	495.23	355.02	274.78	183.26
Operating Income	459.64	-242.84	-217.02	-397.45	-538.06	-505.91
Net Income	549.87	-162.95	-137.83	-278.58	-457.33	-451
Earnings Per Share	2.07	-0.62	-0.52	-1.09	-1.91	-1.88
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025
China	1,632	802.64
Overseas	-	7.55
Total	1,640	810.19

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	2,470	2,031	2,194	2,247	1,046	1,202
Total Debt	812.94	1,133	1,039	888.35	547.8	223.57
Net Cash (Debt)	1,657	898.42	1,155	1,358	498.18	978.32
Net Cash Growth	63.57%	-22.21%	-14.97%	172.65%	-49.08%	-36.78%
Net Cash Per Share	6.25	3.42	4.36	5.31	2.08	4.08

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	796.75	-28.78	38.2	-232.75	-370.34	-454.62
Capital Expenditures	-151.17	-181.47	-95.69	-62.6	-88.62	-70.74
Free Cash Flow	645.58	-210.25	-57.49	-295.35	-458.97	-525.36
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	93.31%	89.89%	92.92%	91.87%	90.89%	96.27%
Operating Margin	28.02%	-29.96%	-40.72%	-102.85%	-177.98%	-265.77%
Pretax Margin	33.37%	-20.81%	-29.09%	-77.40%	-161.41%	-244.35%
Profit Margin	33.52%	-20.11%	-25.86%	-72.09%	-151.28%	-236.92%
FCF Margin	39.36%	-25.94%	-10.79%	-76.43%	-151.82%	-275.98%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	67.65	35.51	35.51	35.51	35.51	-
PS Ratio	20.77	30.28	30.95	36.26	33.11	74.13